摘要
目的:探讨促红细胞生成素(EPO)和受体(EPOR)在前列腺癌(PCa)组织中的表达,并进一步阐述EPO和EPOR在前列腺癌发生发展中所起的作用。方法:应用免疫组化SP法检测30例前列腺癌根治术组织标本中癌与增生(BPH)组织的EPO和EPOR表达及30例正常前列腺组织(NP)中的EPO和EPOR表达。前列腺癌分级采用Gleason评分。半定量EPO和EPOR评分分析免疫组化结果。同时根据细胞染色强度区分为过表达和正常表达。统计学分析采用配对样本比较Wilcoxon的秩和检验及线形回归分析。结果:大部分前列腺癌均可见EPO和EPOR同时过表达,但是前列腺增生组织只有EPO过表达;正常前列腺组织没有EPO和EPOR过表达。前列腺癌和良性前列腺增生的EPO免疫组化评分中位数为2.38和0.93(P<0.01);前列腺癌和良性前列腺增生的EPOR免疫组化评分中位数为2.50和0.68(P<0.01)。前列腺增生和前列腺癌的EPO和EPOR表达密切相关,但是前列腺癌的Gleason评分和EPO以及EPOR评分没有相关性(P值均>0.05)。结论:EPO和EPOR同时过表达促进前列腺癌发生发展,但是相对于EPO的过表达,EPOR过表达是前列腺癌发生更为重要的早期事件;前列腺癌组织中EPO和EPOR表达差异,提示除了缺氧外,可能还有其它机制参与EPOR的过表达。
Objective：To investigate differential up-regulation of erythropoietin（EPO） and its receptor（EPOR） in benign and malignant prostatic tissue.Methods：The expression of EPO and EPOR was analyzed by means of immunohistochemical technique in 30 Prostatic Carcinoma（PCa）tissues from radical prostatectomy specimens containing benign prostate hyperplasia（BPH） tissue,and another 30 normal prostate（NP） tissues.PCa tissues were graded with Gleason system.Semiquantitative EPO and EPOR scores were used to evaluate their expressing levels which were also classified with overexpression and normal expression.Results：Concurrent over-expression of EPO and EPOR was only shown in the majority of PCa but over-expression of EPO was also shown in BPH tissue;no over-expression of EPO and EPOR was observed in normal prostate tissues.PCa had significantly higher median EPOR and EPO score than BPH（2.50 VS 0.68,P0.01;2.38 VS 0.93,P0.01）.There was significant relationship between EPO and EPOR score in BPH and PCa;but no association between EPOR or EPO score and Gleason score in PCa.Conclusion：Concurrent up-regulation of EPO and EPOR makes an important role in development of prostate cancer.Compared with up-regulation of EPO,up-regulation of EPOR is a more important event for prostate carcinogenesis.Differential over-expression of EPOR and EPO in benign and malignant prostatic tissue is ascribed to different mechanisms involved in up-regulation between EPO and EPOR.
出处
《现代生物医学进展》
CAS
2012年第36期7070-7072,7076,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金面上项目(81070602)
